Record licensing deals, a reopened Hong Kong IPO window, US tariffs and BIOSECURE, and a generic GLP-1 wave from India. How 2026 moved biotech's centre of gravity towards Asia, and what it will take to keep it.
Six figures that capture how far, and how fast, Asia's life sciences industry moved this year.
China out-licensing value to 8 October, above 2025's full-year record of $138.8 bn
AstraZeneca's upfront to CSPC for eight obesity and diabetes programmes
Chapter 18A biotech listings in Hong Kong since 2018, with 11 in the first half of 2026
Default US Section 232 tariff on imported patented medicines, with 15% for Japan and Korea
Monthly price of India's first generic semaglutide, launched on 20 March
Samsung Biologics' total biomanufacturing capacity, including its new US site
The complete year-in-review, designed for leadership teams planning 2027.
Your download has started. If it did not, use the button below.
Download the PDF again Read the cover story online →China-originated out-licensing beat 2025's full-year total with almost three months to spare, driven by ADCs, bispecifics and obesity assets. The bigger story is the cheques: average upfronts on China-to-West deals more than tripled since 2022.
Hong Kong posted its strongest first-half IPO run in five years, Western biotechs began filing confidentially there, and AI-native drug discovery reached public markets. But money flowed to late-stage assets and proven platforms, leaving the middle of the pipeline to fight for funding.
The 2 April proclamation put a 100% tariff on patented drug imports, then softened it with deal rates and a generics carve-out. BIOSECURE added a national security filter, with its list of companies of concern due by December. Most of Asia is sheltered for now. Sheltered is not the same as safe.
Samsung Biologics ran its first four plants at full capacity, added a US site and raised guidance. Indian CRDMOs stand to gain about $700 million a year from supply chain diversification. The winners were not those who replaced China, but those who became the obvious second answer.
When the patent expired on 20 March, India became one of the first major markets where generic semaglutide could compete freely. Prices fell sharply, launches came within days, and exporters set their sights on dozens of markets. The real test now is quality at scale.
Asia is no longer simply where pharma comes to make things more cheaply. It is where it comes to find what it cannot discover fast enough itself.From the cover story, BioSpectrum Asia, Year in Review 2026
BioSpectrum Asia's editorial read on each market's momentum in 2026, and the test waiting in 2027.
Download the free whitepaper and take the full analysis into your 2027 planning.
Get the free whitepaper